Breast Cancer. UpToDate:
|
|
- Crystal Wells
- 5 years ago
- Views:
Transcription
1 Breast Cancer UpToDate: - For patients with HER2-positive breast cancer, HER2-directed agent trastuzumab with or without pertuzumab should be added to the chemotherapy regimen as neoadjuvant or systemic therapy. Pertuzumab is NOT indicated in adjuvant setting at this time. Introduction: Sporadic (>90%), familial (< 10%) Risk Factors: Biology: - Genetics/heraditary: * BRCA1/BRCA2: high risk * Others: Li-Fraumeni syndrome (p53), Cowden's syndrome (PTEN), Peutz-Jegher's syndrome (STK11), Ataxia-telangiectasia (ATM). - High-risk lesions: Relative risk >4 * Atypical ductal hyperplasia (ADH), LCIS, - Hormones: OCP low risk (HR=1.24), abnl mammo after 1y risk of nodal involvement or distant metastasis at diagnosis (for post-menopausal woman). - Radiation exposure before age 40y A. ER/PR: PR downstream to ER - ER(+)/PR(+): grow slowly, better differentiated. better prognosis. - ER(+)/PR(-): women > 50y, larger tumors, nodal involvement B. HER2- positive: 20% in breast cancers. C. BRCA1: ER/PR(-), higher grade, risk of both breast and ovarian cancers. BRCA2: ER/PR(+), luminal-like, risk of breast ca, less so of ovarian cancer D. Histology: - Luminal A: ER(+) best prognosis - Luminal B: ER(-), variable expression of Her2 poor prognosis - Her3-enriched: Her2(+)/ER(-) poor prognosis, respond to anti-her2. - Basal-like: triple negative worst prognosis Symptoms: Diagnosis: Breast mass 1) Gail model: assess woman's risk for developing breast cancer - Includes: age at menarche, age at first live birth, number of previous biopsies and presence of atypia, number of first-degree female relatives with breast cancer. 2) Screening Mamo (40-74 yrs): screening for breast cancer mortality. - MRI indicated for high-risk patients (known BRCA mutations, untested first-degree relative BRCA mutation carrier, radiation exposure to chest between age 10 and 30, Li- Fraumeni syndrome, Cowden syndrome). 3) Biopsy Pathology Pathology: A. DCIS: Comedo (high-grade) Page 1 of 8
2 * Cribriform, Papillary, Solid (low or intermediate grade) B. Invasive breast cancer: - Infiltrating ductal carcinoma (70-80%) - Infiltrating lobular carcinoma (5-10%): multicentric, bilateral, ER-positive, metastasize late (to unusual locations). - Others types: * Favorable: Tubular, Mucinous (colloid), Adenoid cystic (even larger size) * Intermediate: Medullary, Metaplastic. * Aggressive: Micropapillary (early nodal mets), Mixed (tubulolobular) C. Staging T0, Tis, T1: <2cm T1mic: <0.1cm T1a: cm T1b: cm T1c: 1-2 cm T2: 2-5 cm T3: >5cm T4: any size with direct invastion to chest wall and/or skin T4a: Chest wall (but not to pectoralis muscle) T4b: Skin (same side) T4c: Both chest wall and skin T4d: Inflammatory ca N1: Movable Axillary LN, Ipsilateral N2: Unmovable LN N2a: fixed/matted, ipsilateral axillary LN N2b: palpable ipsilateral internal mammary LN wihout palpable axillary LN N3: N3a: ipsilateral infraclavicular LN N3b: ipsilateral internal mammary + axillary LN N3c: ipsilateral supraclavicular LN Stage Tumor work-up : Tis, N0, M0 DCIS H&P,lab I: T1 (include T1mic), N0, M0 Early H&P, lab IIA: T0-T1, N1, M0 local Bone scan and CT T2, N0, M0 invasive as clin indicated IIB: T2, N1, M0 BC Page 2 of 8
3 T3, N0, M IIIA: T3, N1, M0 Bone scan, CT T0-T3, N2, M0 Bone scan, CT IIIB: T4, N0-N2, M0 staging, IIIC: anyt, N3,M0 PET-CT (opt) IV: anyt, anyn, M Prognosis: A. DCIS Recurrence Score: - Grade: high-grade (comedo subtype) local recurrence poorly differentiated if recur worse prognosis - Margin: negative margin (<10mm) in breast recurrence. B. Prognostic factors for local invasive breast cancer: Prognostic Factors Predictive Factors Nodal status Steroid receptors Tumor size Her2 Steroid receptors Multigene assay Her2 Histologic grade Histologic subtype Proliferative rate Age C. Molecular Prognosis: - ER (+) tumor: persistent risk of tumor relapse even after many years. - ER (-) tumor: respond better to chmo. - HER over expression: relative resistance to tamoxifen and sensitivity to anthracyclines. Tx Principle: A. Carcinoma In-Situ: 1) LCIS: No palpable mass, diffuse, high ER/PR expression. - Dx: Incidental finding on biopsy. bilateral mamo r/o any invasive - Tx: Wide excision, plus chemoprevention (No RT) * Tamoxifen 5 years (56% risk reduction in P1). Or Raloxifen (postmenopausal women - STAR trial). AI has NO preventative role in this setting. - Special: for pleomorpic LCIS, managed as DCIS (controversial?). 2) DCIS: - Dx: bilateral mamo. ER/PR status. NO need to test Her2! - Tx: Lumpectomy, + whole breast RT (cat 1) Tamoxifen x 5yrs (prevention) *AI or chemo has no role in this setting. * Sentinel lymph node (SNB) indicated only for high-risk DCIS: microinvasion, Page 3 of 8
4 extensive, size >5cm, or high-grade. * Contraindication of lumpectomy: pregnancy, more than one primaries in different quadrants, previous RT to breast, persist margin. - Recurrent DCIS: either mastectomy or recision plus RT B. Microinvasive Breast Cancer: T1mic, a/w DCIS (larger size, multicentric, high-grade). - Dx: Palpable mass (common) biopsy ER/PR, Her2 - Tx: Lumpectomy SLN biopsy * For tumor ER/PR (+), node (-) or microscopic invasion node (<2mm, pn1mic) adj Tamoxifen or AI (NO chemo) * For tunmor ER/PR (-), node (+) including pn1mic (<2mm) adj chemo +/- anti- Her2 therapy C. Invasive Breast Cancer (stage I to IIIA): 1) Local Tx: Surgery plus radiation principle - Lumpectomy + adj RT to whole breast (category 1). * (+) SLBN node dissection - Mastectomy SLNB adj RT based on SLNB: * (-) axillary nodes: NO RT, except T >5cm, or margin (+) or close margin (<1mm) * > 4 (+) axillary nodes adj RT to chest wall (category1). * 1-3 (+) axillary nodes controvertial. 2) Adj Chemo: effective regardless of ER/PR status, start 4-6 wks after sugery. - CALGB 947: Dose dense is superior. - Less-aggressive regimen: AC x 4 cycles, CMF x 6 months, TC=AC, DC? - Aggressive chemo: AC-T, AC-TH-H, TCH, FAC or FEC (superior to AC). 3) Adj Endocrine: indicated for all ER/PR-positive tumors, except for patients > 60y, node (-), T<1cm. - Do NOT give hormone and chemo together (hormone after chemo and RT). - Pre-menopausal: Taxmixifen x 5 yrs ± ovarian suppression (OA) or ablation switch to AI for another 5 yrs (cat1) after post-menopausal * Tamoxifen recurrence by 39% and death by 31%, second primary BC - Post-menopausal: AI x 5ys; or Taxmoxifen x 2-3 ys AI x 5ys; or AI x 2-3 ys Tamoxifen x 5 ys. * ATAC (Anastrozole, Tamoxifen Alone or in Combination): Anastrozole vs Tamoxifen superior DFS, but no OS difference in post-menopausal woman. * BIG 1-98 trial: Letrozol vs Tamoxifen (also no OS benefit) * MA 17 trial: "tamoxifen x 5ys letrozole" vs tamoxifen alone ( DFS, not OS) * IES (Intergroup Exemstane Study): tamoxifen 2-3 yrs exemstane vs tamoxifen 5 ys ( DFS, trend to OS). * META: "tamoxifen 2-3 ys anastrozole" vs tamoxifen 5 ys ( DFS, OS) 4) Adj Anti-Her2 Therapy (Trastuzumab): indicated for all node-positive and node negative tumor >1cm (category 1). - Concurrent chemo and trastuzumab followed by maintenance trastuzumab x total of 12 mos DFS (HR=0.52), OS (HR=0.61) * AC-TH-H (NSABP B-31, NCCTG-9831). * FinHER: 9 wk of trastuzumab no improvement in DFS, OS * HERA: assess longer (>1 yr) duration of trastuzumab (ongoing) Page 4 of 8
5 * BCIRG-006: non-trastuzumab regimen AC-TH-H TCH (lowest cardiac side effect). Avoid CMF for anti-her2 therapy. - Laptinib: DO NOT use in adj setting. 5) Bone loss prevention: VitD/Ca, prolia every 6 months while on AI. - DEXA annually - Premenopausal: tamoxifen bone loss. Postmenopausal: tamoxifen bone loss - Postmenopausal: AI bone loss. 6) Algorithm (Board Review) - Node (-) BC of pure tubular or colloid histogy excellent prognosis after surgery NO adj chemo regardless of tumor SIZE - Node (+) BC (>2mm node involvement): adj chemo - Node (-), ER (-): if T >1cm adj chemo if T cm prefer adj chemo > observation if T <0.5cm observe (NO chemo) - Node (-), ER (+): if T < 0.5 cm observe (NO chemo) if T > 0.6 cm, Oncotype DX (21-gene -RS Score) RS <18 low risk No chemo RS=18-30 intermediate-risk TailorOx Trial? RS > 31 high-risk adj chemo ( DFS by 22%) - Node (-), ER (+), age >70, very small and well-differentiated BC: Lumpectomy alone with wide negative margin (>10mm) NO RT post surgery (RCT - small difference in local recurrence but no OS difference). - Old woman: if life span <5 yrs no hormonal tx. - Male BC: prognosis and treatment are the same as woman BC. - Breast cancer in pregnancy: chemo can be given after 1st trimester. - Obese woman BC: standard weight based drug dose should be administered to all patients. DO NOT use ideal body weight. D. Locally Advanced Breast Cancer: neoadj therapy 1) Rationale: - Debulky, chance of BCT (for T>3 cm or palpable nodes BC or inflammatory BC) - In vivo drug testing - However, no survival and PFS benefit compared to adj chemo. 2) Regimen: the same as those of adj chemo - Add trastuzumab to neoadj chemo recommended for Her2+ tumor (similar to adj chemo) improve response rate complete trastuzumab for a total of 52 wks after surgery. (Trials: *Neoadj Herceptin Trial (NOAH), * GeparQuattro, * NeoALTTO, etc). - Important: complete all neoadj chemo in pre-op setting, rather than deviding it between pre- and post-op. - Assess response before surgery: For non-responder (rare) no proven benefit to switch chemo (GeparTrio trial) consider neoadj XRT or hormonal therapy. - When neoadj therapy is indicated, neoadj chemo is preferred. Neoadj endocrine Page 5 of 8
6 therapy is an option for ER/PR (+) tumor. AI (preferred) as neoadj setting for postmenopausal woman. E. Metastatic Breast Cancer (MBC): 1) Dx: re-biopsy is essential at metastasis because discordance in ER/PR expression (14%) and Her2 expresson (5%). 2) ER/PR-positive and Her2-negative tumors: - Premenopausal: * Ovarian ablation or suppression * Endocrine therapy as for post-menopausal women. - Post-menopausal: * 1st line: Ibrance/Femara * 2nd line: Falsodex/Femara Aromasin/Affinitor - Visceral crisis: initiate chemotherapy. 3) Her2-positive tumors: - ER/PR-positive endocrine therapy +/- Her2-targeted chemotherapy - ER/PR-negative Pertuzumab + trastuzumab + taxane or T-DM1 or trastuzumab + chemo. 4) Trastuzumab-refractory tumors: continue Her2 blockade - If interval between adj tx and relapse > 12 mos, repeat "trasutuzumab + taxane" - If interval between adj tx and relapse <12 mos or progress while receiving trastuzumab: * laptinib + xeloda * "Lapatinib + Trastuzumab" DFS, trend to OS * "Pertuzumab + Trastuzumab" DFS, trend to OS * "T-DM1 (Trastuzumab emtansine)" DFS, OS (HR 0.62) - EMILIA. 5) Triple negative metastatic breast cancer - Basal-like moleuclar subtype, BRCA1(+) - Symptoms: aggressive behavior, high risk of visual and brain metastasis than soft tissue, bone mets, early relapse - Chemotherapy: AC-T or single agent. "Bev + Taxel" is good for Her2- neg tumor (do not use Bev in Her2 positive BC). 6) CNS mets: a/w age<40, pulomonary mets, AAF, Her(+), or triple negative. - Tx: Multiple brain mets: "Lapatinib + Capecitabine" before WBRT (LANDSCAPE phase II trial) CNS RR 67%, DFS, OS. * Solitary Met: surgical resection or radiosurgery (SRS), followed by WBRT - Leptomeningeal mets: uncommon (numb chick syndrome) 7) Inflammatory breast cancer (IBC): Median OS < 1yr - Sx: erythema, warmth, and edema (peau d'orange), no breast mass in > 50% of pts - Path: ER-negative, high E-cadherin, TP53 mutation. Page 6 of 8
7 - Dx: Punch biopsy - Tx: Mastectomy (rather than BCT), plus adj XRT. Adj chemo and hormonal therapy similar to other breast cancer. 8) Locoregional Relapse: - In-breast tumor recurrence (IBTR) (occur early within 5-yr): mastectomy - Chest wall recurrence: worse prognosis, surgical resection, f/u by either XRT or chemo - Regional nodal recurrence: full LN dissection followed by adj chemo 9) Special Consideration: 9.1. Phyllodes Tumor: - Path: similar to fibroadenoma, but large size (>2cm), rapid growth. * Benign, Borderline, malignant; * LN metastasis rare, even for malignant tumor. * Distant metastasis does occur. - Dx: US, Core need biopsy. - Tx: Wide local excision (margin >1cm) or lumpectomy. NO SNB is needed. * Benign observe after wide excision. * Bordline or malignant adj RT after wide excision, plus adj chemo reserved for large and recurrent tumor. - Follow-up (sarcoma guideline): H&P, CXR, q 6 mos x 2 yrs, then annually. For high risk (T>5cm) tumor, CT scan q 6 mos x 2 yrs, then annually Breast Cancer in Pregnancy: ER/PR (-), Her2 (+), poorly differentiated - Dx: US (breast densed during pregnancy), MRI not safe - Sx: large tumor, positive nodes or mets - Tx: mastectomy + axillary node dissection (SNB is contraindicated in pregnancy). * 1st trimester: no chemo * After 1st trimester: OK for chemo, - Pregnancy does risk of recurrence. Wait for 2 yrs before conceiving. Follow-Up: A. Follow-up: H&P, annual mamo. NO lab or imaging needed. B. Symptom Management: - Vasomotor Tx: Gabapentin, Venlafaxine or SSR; avoid Estrogen. For woman taking tamoxifen avoid Paroxetine, Fluoxetine - DEXA for osteoporosis. Rx bisphosphonate for osteopenia. Pharmacology: A Tamoxifen: for both pre- and post menopausal women, but the greater benefit for premenopausal woman. - SSRI inhibits CYP2D6 metabolism of tamoxifen to endoxifen (active). However, BIG 1-98 trial no association between CYP2D6 genotype and clinical outcome. So, testing for CYP2D6 genotype is NOT recommended! But avoid CYP2D6 inhibitors (paroxetine, fluoxetine) when taking tamoxifen. - SE: Serious uterine cancer, thromboembolic events Others hot flash, endometrial hyperplasia, polyps fibroid Page 7 of 8
8 B. Raloxifen: for postmenopausal woman only, potential teratogenic - SE: fewer uterine cancer, thromboembolic events, but more musculoskeletal pain, dyspareunia, and weight gain C. Aromatase Inhibitors (AI): - Non-steroidal Letrozol (Femara), Anastrozole (Arimidex); - Steroidal: Exemestrane (Aromasin) - SE: Bone loss, osteoporosis, joint pain, stiffness, risk of ischemic cardiovascular diseases, lower risk of VTE compared to Tamoxifen. D. Perjeta (Pertuzumab): Her2/neu receptor dimerization inhibitor. Front-line Tx in combination with transtuzumab and docetaxel for Her2-positive metastatic breast cancer. * CLEOPATRA study very positive - SE: diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy. LVF (similar to trastuzumab) * Echo q 3months, hold Perjeta if ef <40% or ef 40-45% with >10% absolute decrease before pre-treatment value. Repeat echo in 3-weeks, resume Perjeta if ef>45%. Page 8 of 8
Breast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationJose A Torres, MD 1/12/2017
Jose A Torres, MD 1/12/2017 Background Globally leading cause of cancer related death in women ~249,000 Americans diagnosed with invasive breast cancer ~40,890 will die of their disease Breast cancer risk
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationSystemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative
Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More information4/13/2010. Silverman, Buchanan Breast, 2003
Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More informationBreast Cancer. Breast Cancer. Established breast cancer risk factors. Established breast cancer risk factors. Cancer incidence.
Breast Cancer A buffet of breast cancer topics Wendy Y. Chen, MD MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Disclosures: none Not related to anything presented in this lecture Wendy
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationEvolving Practices in Breast Cancer Management
Evolving Practices in Breast Cancer Management The Georgia Tumor Registrars Association 2016 Priscilla R. Strom, MD, FACS Objectives 1. understand newer indications for neoadjuvant treatment 2. understand
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationBREAST SURGERY PROGRESS TEST Name:
General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased
More informationCompleting the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017
Completing the Puzzle AJCC TNM Staging Breast Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017 OBJECTIVES Understanding of Breast TNM staging Identify clinical
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationBreast cancer staging update. Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director
Breast cancer staging update Ekaterini Tsiapali, MD, FACS MedStar Regional Breast Program Site Director 1 1 Review of the AJCC 8 th edition breast cancer staging Review of genomic assays as stage modifiers
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationBreast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.
Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following
More informationBreast Cancer Statistics
1 in 8 Breast Cancer Statistics Incidence Mortality Prevalence 2 Breast Cancer Incidence Breast Cancer Mortality Breast Cancer Prevalence ~$100,000 Female Breast Anatomy Breasts consist mainly of fatty
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Breast 4/4/13. NAACCR Webinar Series Collecting Cancer Data Breast
Collecting Cancer Data Breast NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More information制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識
2006.03.09 制定阮綜合醫療社團法人阮綜合醫院乳癌 (Breast Cancer) 治療共識 2007.10.01 修訂 2009.04.22 修訂 2010.04.07 審閱 LCIS (Lobular Carcinoma in Situ) 2011.12.07 修訂 2012.03.07 修訂 Diagnosis Workup Risk Reduction Surveillance Biopsy
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationIncreased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017
Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationAdvances in Neoadjuvant and Adjuvant Therapy for Breast Cancer
Advances in Neo and Adjuvant Therapy for Breast Cancer Nicole Kounalakis, MD, and Christina Finlayson, MD OVERVIEW Systemic therapy for breast cancer is evolving rapidly. The medical treatment of cancer
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationBREAST CANCER BREAST CANCER
BREAST CANCER George Raptis, M.D., M.B.A Division of Medical Oncology & Hematology College of Physicians & Surgeons Columbia University BREAST CANCER Epidemiology - Commonest cancer in women - About 235,000
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More information- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer
Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.
More informationDepartment of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
Department of Endocrine & Breast Surgery Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India Evidence-Based Pragmatic SGPGI Breast Cancer Management Protocols (Summary) Background:
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationIdeal neo-adjuvant Chemotherapy in breast ca. Dr Khanyile Department of Medical Oncology, University of Pretoria
Ideal neo-adjuvant Chemotherapy in breast ca Dr Khanyile Department of Medical Oncology, University of Pretoria When is neo-adjuvant Chemo required? Locally advanced breast ca: - Breast conservative surgery
More informationQuiz. b. 4 High grade c. 9 Unknown
Quiz 1. 10/11/12 CT scan abdomen/pelvis: Metastatic liver disease with probable primary colon malignancy. 10/17/12 Colonoscopy with polypectomy: Adenocarcinoma of sigmoid colon measuring at least 6 mm
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationFor more information about how to cite these materials visit
Author: Vincent M. Cimmino, M.D., 2011 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Share Alike 3.0 License: http://creativecommons.org/licenses/by-sa/3.0/
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationBreast Cancer FAQ. How does Breast Cancer spread? Breast cancer spreads by invading into
FAQ Breast Cancer What is Breast Cancer? Breast Cancer is the second leading cause of cancer deaths in women today (second to lung cancer) and is the most common cancer among women excluding non-melanoma
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationBreast. Presentation Outline
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationBreast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.
Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationEndocrine Therapy of Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationBreast Cancer Treatment, Outcomes and Recent Advances. Ogori N Kalu, MD, MS Director Breast Surgery-UH Asst. Prof of Surgery Rutgers NJ Med School
Breast Cancer Treatment, Outcomes and Recent Advances Ogori N Kalu, MD, MS Director Breast Surgery-UH Asst. Prof of Surgery Rutgers NJ Med School National Statistics 1 in 8 women in the U.S. (12-13%) will
More informationChemotherapy for Isolated Locoregional Recurrence
Chemotherapy for Isolated Locoregional Recurrence Michelle Melisko MD Assistant Clinical Professor UCSF Helen Diller Family Comprehensive Cancer Center MBC and Improved Median Survival with New Therapies
More informationOBJECTIVES CASE 1. Breast Cancer Risk Factors, Genetics, Screening, Diagnosis AGE. Risks of developing breast cancer
Breast Cancer Risk Factors, Genetics, Screening, Diagnosis Bhuvaneswari Ramaswamy, MD, MRCP Assistant Professor of Internal Medicine Breast Cancer Fellowship Program Director Medical Director of Clinical
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBreast Cancer Treatment
Breast Cancer Treatment Treatment 2 aspects 1. Treatment of the breast itself: Local Treatment 2. Treatment of the whole body = Systemic treatment Local Treatment Surgery +/- Radiation Usually: a. Breast
More informationBreast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016
Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient
More information